loading
Precedente Chiudi:
$5.15
Aprire:
$5.18
Volume 24 ore:
763.76K
Relative Volume:
0.86
Capitalizzazione di mercato:
$454.61M
Reddito:
$380.79M
Utile/perdita netta:
$49.27M
Rapporto P/E:
7.2857
EPS:
0.7
Flusso di cassa netto:
$10.68M
1 W Prestazione:
-3.95%
1M Prestazione:
-4.14%
6M Prestazione:
-8.11%
1 anno Prestazione:
+196.51%
Intervallo 1D:
Value
$4.835
$5.20
Intervallo di 1 settimana:
Value
$4.64
$5.40
Portata 52W:
Value
$1.575
$7.27

Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile

Name
Nome
Amylyx Pharmaceuticals Inc
Name
Telefono
617-683-0917
Name
Indirizzo
43 THORNDIKE STREET, CAMBRIDGE
Name
Dipendente
123
Name
Cinguettio
Name
Prossima data di guadagno
2025-03-04
Name
Ultimi documenti SEC
Name
AMLX's Discussions on Twitter

Confronta AMLX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
AMLX
Amylyx Pharmaceuticals Inc
5.10 420.75M 380.79M 49.27M 10.68M 0.70
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.93 25.76B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
445.43 114.53B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.415 40.54M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
84.10 6.44B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.81 65.13B 14.09B 4.50B 2.96B 39.28

Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-05-30 Iniziato TD Cowen Buy
2025-04-07 Aggiornamento Mizuho Neutral → Outperform
2024-11-18 Aggiornamento Robert W. Baird Neutral → Outperform
2024-10-23 Aggiornamento BofA Securities Neutral → Buy
2024-03-18 Downgrade Mizuho Buy → Neutral
2024-03-11 Downgrade Leerink Partners Outperform → Market Perform
2024-03-11 Downgrade Robert W. Baird Outperform → Neutral
2024-03-08 Downgrade Evercore ISI Outperform → In-line
2024-03-08 Downgrade Goldman Buy → Neutral
2024-01-03 Iniziato Robert W. Baird Outperform
2023-12-12 Iniziato Deutsche Bank Buy
2023-07-24 Aggiornamento Goldman Neutral → Buy
2023-03-31 Iniziato Mizuho Buy
2023-01-05 Iniziato BofA Securities Buy
2022-05-25 Iniziato Citigroup Buy
2022-04-01 Downgrade Goldman Buy → Neutral
Mostra tutto

Amylyx Pharmaceuticals Inc Borsa (AMLX) Ultime notizie

pulisher
Jun 02, 2025

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Purchased by Millennium Management LLC - Defense World

Jun 02, 2025
pulisher
Jun 01, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Shareholders to Connect - ACCESS Newswire

Jun 01, 2025
pulisher
Jun 01, 2025

Northern Trust Corp Purchases 11,214 Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World

Jun 01, 2025
pulisher
May 31, 2025

Amylyx Pharmaceuticals (NASDAQ:AMLX) Now Covered by TD Cowen - Defense World

May 31, 2025
pulisher
May 31, 2025

TD Cowen starts Amylyx stock coverage with Buy rating - Investing.com Australia

May 31, 2025
pulisher
May 30, 2025

Amylyx (AMLX) Receives Buy Rating from TD Cowen on Avexitide Pot - GuruFocus

May 30, 2025
pulisher
May 30, 2025

TD Cowen starts Amylyx stock coverage with Buy rating By Investing.com - Investing.com Nigeria

May 30, 2025
pulisher
May 30, 2025

Amylyx (AMLX) Receives Buy Rating from TD Cowen on Avexitide Potential | AMLX Stock News - GuruFocus

May 30, 2025
pulisher
May 30, 2025

Amylyx initiated with a Buy at TD Cowen - TipRanks

May 30, 2025
pulisher
May 29, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Connect - ACCESS Newswire

May 29, 2025
pulisher
May 29, 2025

2025-05-29 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Connect | NDAQ:AMLX | Press Release - Stockhouse

May 29, 2025
pulisher
May 28, 2025

Amyotrophic lateral Sclerosis Market 2025-2032: Top Trends & - openPR.com

May 28, 2025
pulisher
May 28, 2025

🌐 ALS Treatment Market to Hit $1.04 Billion by 2032 | Driven by New Drug Approvals & Asia-Pacific Expansion - openPR.com

May 28, 2025
pulisher
May 27, 2025

Man Group plc Trims Stock Position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World

May 27, 2025
pulisher
May 25, 2025

Bank of America Corp DE Increases Stock Holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World

May 25, 2025
pulisher
May 25, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire

May 25, 2025
pulisher
May 24, 2025

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Sold by D. E. Shaw & Co. Inc. - Defense World

May 24, 2025
pulisher
May 22, 2025

Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

May 22, 2025
pulisher
May 21, 2025

Amylyx Pharmaceuticals to Participate in Upcoming June Investor Conferences - BioSpace

May 21, 2025
pulisher
May 20, 2025

2025-05-20 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Connect | NDAQ:AMLX | Press Release - Stockhouse

May 20, 2025
pulisher
May 20, 2025

Wall Street Analysts See a 105.22% Upside in Amylyx Pharmaceuticals (AMLX): Can the Stock Really Move This High? - Yahoo Finance

May 20, 2025
pulisher
May 20, 2025

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Consensus Rating of “Buy” from Analysts - Defense World

May 20, 2025
pulisher
May 18, 2025

2025-05-18 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Stockholders to Learn More About the Investigation | NDAQ:AMLX | Press Release - Stockhouse

May 18, 2025
pulisher
May 18, 2025

Dimensional Fund Advisors LP Acquires Shares of 54,114 Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World

May 18, 2025
pulisher
May 18, 2025

Head-To-Head Survey: Perrigo (NYSE:PRGO) versus Amylyx Pharmaceuticals (NASDAQ:AMLX) - Defense World

May 18, 2025
pulisher
May 16, 2025

Mizuho Boosts Amylyx Pharmaceuticals (NASDAQ:AMLX) Price Target to $8.00 - Defense World

May 16, 2025
pulisher
May 14, 2025

Mizuho Adjusts Price Target on Amylyx Pharmaceuticals to $8 From $7, Maintains Outperform Rating - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

Amylyx (AMLX) Gets Price Target Boost Following Positive Trial Update | AMLX Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Amylyx price target raised to $8 from $7 at Mizuho - TipRanks

May 14, 2025
pulisher
May 14, 2025

Transcript : Amylyx Pharmaceuticals, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 01 - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

Amylyx Pharmaceuticals (AMLX) Sees Price Target Upgrade by Mizuho | AMLX Stock News - GuruFocus

May 14, 2025
pulisher
May 13, 2025

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Reach Out - ACCESS Newswire

May 13, 2025
pulisher
May 13, 2025

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q1 2025 Earnings Call Transcript - Insider Monkey

May 13, 2025
pulisher
May 13, 2025

Hsbc Holdings PLC Lowers Holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World

May 13, 2025
pulisher
May 13, 2025

Amylyx Pharmaceuticals’ Earnings Call Highlights Progress and Challenges - TipRanks

May 13, 2025
pulisher
May 12, 2025

AMX0035 shows promise in Wolfram syndrome trial By Investing.com - Investing.com South Africa

May 12, 2025
pulisher
May 12, 2025

AMLX Reports Promising Results from HELIOS Trial for Wolfram Syn - GuruFocus

May 12, 2025
pulisher
May 12, 2025

H.C. Wainwright raises Amylyx stock target to $16 on trial hopes By Investing.com - Investing.com South Africa

May 12, 2025
pulisher
May 12, 2025

H.C. Wainwright raises Amylyx stock target to $16 on trial hopes - Investing.com Australia

May 12, 2025
pulisher
May 12, 2025

Amylyx Pharmaceuticals Announces Positive Long-Term Results from Phase 2 HELIOS Clinical Trial of AMX0035 in People with Wolfram Syndrome - BioSpace

May 12, 2025
pulisher
May 12, 2025

Amylyx Pharmaceuticals Announces Positive Long-Term Results From Phase 2 Helios Clinical Trial Of Amx0035 In People With Wolfram Syndrome - marketscreener.com

May 12, 2025
pulisher
May 12, 2025

AMX0035 shows promise in Wolfram syndrome trial - Investing.com Australia

May 12, 2025
pulisher
May 12, 2025

Barclays PLC Cuts Holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World

May 12, 2025
pulisher
May 11, 2025

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Reach Out - ACCESS Newswire

May 11, 2025
pulisher
May 11, 2025

2025-05-11 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Reach Out | NDAQ:AMLX | Press Release - Stockhouse

May 11, 2025
pulisher
May 11, 2025

Class Action Filed Against Amylyx Pharmaceuticals, Inc. (AMLX) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire

May 11, 2025
pulisher
May 11, 2025

HC Wainwright Increases Amylyx Pharmaceuticals (NASDAQ:AMLX) Price Target to $16.00 - Defense World

May 11, 2025
pulisher
May 10, 2025

Amylyx Pharmaceuticals, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationAMLX - ACCESS Newswire

May 10, 2025
pulisher
May 10, 2025

Shareholders of Amylyx Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your RightsAMLX - ACCESS Newswire

May 10, 2025
pulisher
May 10, 2025

Lost Money on Amylyx Pharmaceuticals, Inc.(AMLX)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire

May 10, 2025
pulisher
May 10, 2025

Class Action Filed Against Amylyx Pharmaceuticals, Inc. (AMLX)April 9, 2024 Deadline to Join – Contact Levi & Korsinsky - ACCESS Newswire

May 10, 2025

Amylyx Pharmaceuticals Inc Azioni (AMLX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$1.15
price up icon 6.48%
$31.19
price up icon 3.48%
$584.61
price up icon 1.98%
$306.09
price up icon 0.50%
$4.5994
price up icon 2.21%
$490.81
price up icon 0.11%
Capitalizzazione:     |  Volume (24 ore):